In conclusion, we have shown strong and tolerable potentiation of PRRT by DNA-PKcs inhibitor AZD7648 in preclinical neuroendocrine tumor in vitro and in vivo models. The gene discussed is PRKDC; the disease is neuroendocrine neoplasm.